ICU Medical, Inc. (NASDAQ:ICUI) Shares Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System raised its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 14.6% during the third quarter, Holdings Channel.com reports. The institutional investor owned 11,800 shares of the medical instruments supplier’s stock after buying an additional 1,500 shares during the period. Louisiana State Employees Retirement System’s holdings in ICU Medical were worth $2,150,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Motco acquired a new stake in shares of ICU Medical during the first quarter valued at $29,000. Innealta Capital LLC acquired a new stake in shares of ICU Medical during the 2nd quarter worth about $32,000. Hexagon Capital Partners LLC grew its holdings in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 122 shares in the last quarter. Allworth Financial LP raised its position in shares of ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 100 shares during the last quarter. Finally, EntryPoint Capital LLC lifted its stake in shares of ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 395 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Insider Transactions at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,552 shares of company stock valued at $6,679,322 over the last 90 days. Corporate insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Jefferies Financial Group assumed coverage on ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock. KeyCorp lifted their price target on ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Finally, Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $170.25.

ICU Medical Price Performance

ICUI stock opened at $175.07 on Wednesday. The company has a market cap of $4.27 billion, a PE ratio of -71.46 and a beta of 0.66. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. The stock has a 50-day moving average price of $173.34 and a two-hundred day moving average price of $136.18. ICU Medical, Inc. has a 12-month low of $78.28 and a 12-month high of $188.53.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter in the previous year, the business earned $1.58 EPS. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, research analysts predict that ICU Medical, Inc. will post 3.81 EPS for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.